GPT Healthcare Reports Q3FY26 Results with Revenue Growth of 16.81% YoY

1 min read     Updated on 27 Jan 2026, 09:10 PM
scanx
Reviewed by
Shriram SScanX News Team
Overview

GPT Healthcare announced Q3FY26 results showing revenue growth of 16.81% to ₹121.6 Cr, though profitability declined with PAT dropping 23.50% to ₹9.4 Cr. The company maintained operational momentum with ARPOB at ₹38,797 and continued network expansion including CTVS commissioning at ILS-Dum Dum.

31074009

*this image is generated using AI for illustrative purposes only.

GPT Healthcare Limited has announced its Q3FY26 financial results, reporting revenue of ₹121.6 Cr for the quarter ended December 31, 2025, marking a 16.81% year-on-year growth. The company submitted its comprehensive financial results and press release under Regulation 30 of SEBI regulations on February 2, 2026.

Q3FY26 Financial Performance

The company demonstrated strong revenue momentum with quarterly revenue reaching ₹121.6 Cr compared to ₹104.1 Cr in Q3FY25. However, profitability metrics showed pressure with EBITDA declining 4.38% to ₹22.2 Cr and PAT dropping 23.50% to ₹9.4 Cr. EBITDA margins compressed to 18.20% from 22.23% in the previous year.

Metric: Q3FY26 Q3FY25 YoY Change
Total Revenue: ₹121.6 Cr ₹104.1 Cr +16.81%
EBITDA: ₹22.2 Cr ₹23.1 Cr -4.38%
EBITDA Margin: 18.20% 22.23% Compression
PAT: ₹9.4 Cr ₹12.1 Cr -23.50%

Nine-Month Performance Overview

For 9MFY26, the company achieved total revenue of ₹350.5 Cr, representing 12.12% year-on-year growth from ₹312.6 Cr in 9MFY25. Despite revenue growth, EBITDA declined 6.39% to ₹65.1 Cr with margins compressing from 22.26% to 18.58%. PAT for the nine-month period stood at ₹27.6 Cr, down 25.32% from ₹37.0 Cr in the previous year.

Parameter: 9MFY26 9MFY25 Change
Total Revenue: ₹350.5 Cr ₹312.6 Cr +12.12%
EBITDA: ₹65.1 Cr ₹69.6 Cr -6.39%
PAT: ₹27.6 Cr ₹37.0 Cr -25.32%

Operational Highlights and Network Expansion

The company maintained competitive ARPOB at ₹38,797 while achieving 55% occupancy excluding the newly commenced Raipur facility. Including Raipur, overall network occupancy stands at 45%. The company commissioned CTVS (Cardiothoracic and Vascular Surgery) services at ILS-Dum Dum, providing complete cardiac care under one roof. The Raipur facility continues scaling efficiently while the Jamshedpur project progresses as planned.

Management Commentary

Chairman Dr. Om Tantia highlighted the company's disciplined execution and improving operating metrics. He emphasized the completion of over 750+ robotic surgeries at ILS Salt Lake, reinforcing the company's position in advanced minimally invasive care. The payer mix remained predominantly cash and insurance, reflecting revenue quality and financial resilience while serving the aspirational middle-to-high income population.

Historical Stock Returns for GPT Healthcare

1 Day5 Days1 Month6 Months1 Year5 Years
+0.04%+0.37%-3.98%-19.57%-7.35%-35.53%

GPT Healthcare Appoints MUFG Intime India as Investor Relations Agency

1 min read     Updated on 26 Dec 2025, 12:46 PM
scanx
Reviewed by
Shriram SScanX News Team
Overview

GPT Healthcare Limited has appointed MUFG Intime India Private Ltd as its investor relations agency effective January 1, 2026, to strengthen investor communication and enhance capital market visibility. The company has designated ir@gptgroup.co.in for investor queries and made the announcement in compliance with SEBI regulations.

28279004

*this image is generated using AI for illustrative purposes only.

GPT Healthcare Limited has announced a strategic appointment to enhance its investor relations capabilities. The healthcare company has engaged MUFG Intime India Private Ltd as its investor relations agency, marking a significant step toward strengthening its capital market presence.

Appointment Details

The company has formally appointed MUFG Intime India Private Ltd to provide investor relations advisory services, with the engagement becoming effective from January 1, 2026. This appointment was announced through a regulatory filing under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Parameter: Details
Service Provider: MUFG Intime India Private Ltd
Service Type: Investor Relations Advisory Services
Effective Date: January 1, 2026
Regulatory Framework: SEBI Listing Regulations

Strategic Objectives

The appointment is designed to achieve multiple strategic objectives for GPT Healthcare Limited. The company aims to strengthen its investor communication framework, enhance transparency in its operations, and improve its overall visibility in the capital markets. These initiatives are expected to facilitate better engagement with existing and potential investors.

Communication Infrastructure

As part of this investor relations enhancement initiative, GPT Healthcare Limited has established dedicated communication channels for investor engagement. The company has designated ir@gptgroup.co.in as the specific email address for all investor-related queries, concerns, and requests. This centralized communication approach is intended to streamline investor interactions and ensure prompt responses to stakeholder inquiries.

Regulatory Compliance

The announcement demonstrates GPT Healthcare Limited's commitment to maintaining robust corporate governance standards and regulatory compliance. The appointment was made in accordance with Regulation 30 of the SEBI Listing Regulations, ensuring full transparency with stock exchanges and investors. The company has also made this information available on its website at www.ilshospitals.com , further emphasizing its commitment to transparent communication.

This strategic move reflects GPT Healthcare Limited's focus on enhancing its investor relations capabilities and maintaining strong relationships with the investment community through professional advisory services.

Historical Stock Returns for GPT Healthcare

1 Day5 Days1 Month6 Months1 Year5 Years
+0.04%+0.37%-3.98%-19.57%-7.35%-35.53%

More News on GPT Healthcare

1 Year Returns:-7.35%